Comprehensive Biology and Genetics Compendium of Wilms Tumor Cell Lines with Different WT1 Mutations

Simple Summary Wilms tumor is a childhood kidney tumor arising from embryonal cells. Wilms tumors are heterogeneous with several distinct subgroups that differ in their response to treatment. The genetic basis for these diverse forms of Wilms tumor is not fully understood. One subgroup of Wilms tumors is associated with mutations in the WT1 gene, encoding a transcription factor with a role in early kidney differentiation. Patients with WT1 mutant Wilms tumor may harbor germline mutations in this gene. Cell lines from Wilms tumors are notoriously difficult to establish and only few exist. We developed a method to cultivate cells from the WT1 mutant subtype of Wilms tumors and have established 11 cell lines with different mutations in WT1 to date. These cells will be instrumental to study the biology and genetics ultimately to develop precision treatments Abstract Purpose: WT1 mutant Wilms tumors represent a distinct subgroup, frequently associated with CTNNB1 mutations. The genetic basis for the development of this subtype is currently not fully understood. Methods: Live WT1 mutant Wilms tumors were collected during surgery of patients and cell cultures established in mesenchymal stem cell medium. They were studied for mutations in WT1 and CTNNB1, their differentiation capacity and protein activation status. Four cell lines were immortalized with a triple mutant ts SV40 largeT antigen and Telomerase. Results: 11 cell lines were established from Wilms tumors of nine patients, including a left and right tumor from the same patient and a primary and second tumor from another patient. Six patients had germ line and three were tumor specific mutations. All cell lines harbored only mutant or deleted WT1 genes. CTNNB1 was wild type in three, all others carried mutations affecting amino acid S45. They had variable and limited capacities for mesenchymal differentiation, a high migratory capacity and a low invasive potential. All cells showed an activation of multiple receptor tyrosine kinases and downstream signaling pathways. Conclusions: These cell lines represent an important new tool to study WT1 mutant Wilms tumors, potentially leading to new treatment approaches.

[1]  Ying Xu,et al.  ERK/MAPK signalling pathway and tumorigenesis , 2020, Experimental and therapeutic medicine.

[2]  J. Mora,et al.  WT1-Mutant Wilms Tumor Progression Is Associated With Diverting Clonal Mutations of CTNNB1. , 2019, Journal of pediatric hematology/oncology.

[3]  K. Kayasut,et al.  Senescence Process in Primary Wilms' Tumor Cell Culture Induced by p53 Independent p21 Expression , 2016, Journal of Cancer.

[4]  J. Mora,et al.  Establishment of a Conditionally Immortalized Wilms Tumor Cell Line with a Homozygous WT1 Deletion within a Heterozygous 11p13 Deletion and UPD Limited to 11p15 , 2016, PloS one.

[5]  E. Toska,et al.  Classification of a frameshift/extended and a stop mutation in WT1 as gain-of-function mutations that activate cell cycle genes and promote Wilms tumour cell proliferation , 2014, Human molecular genetics.

[6]  P. Neven,et al.  A Core Invasiveness Gene Signature Reflects Epithelial-to-Mesenchymal Transition but Not Metastatic Potential in Breast Cancer Cell Lines and Tissue Samples , 2014, PloS one.

[7]  Arthur Wuster,et al.  DeNovoGear: de novo indel and point mutation discovery and phasing , 2013, Nature Methods.

[8]  M. Gessler,et al.  Characterization of primary wilms tumor cultures as an in vitro model , 2012, Genes, chromosomes & cancer.

[9]  S. Thomson,et al.  Inducible expression of TGFβ, Snail and Zeb1 recapitulates EMT in vitro and in vivo in a NSCLC model , 2011, Clinical & Experimental Metastasis.

[10]  Fei Gao,et al.  Wt1 ablation and Igf2 upregulation in mice result in Wilms tumors with elevated ERK1/2 phosphorylation. , 2011, The Journal of clinical investigation.

[11]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[12]  J. Mora,et al.  Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm. , 2010, Human molecular genetics.

[13]  Petros Koumoutsakos,et al.  TScratch: a novel and simple software tool for automated analysis of monolayer wound healing assays. , 2009, BioTechniques.

[14]  G. M. Mulder,et al.  Epidermal growth factor receptor signaling in the kidney: key roles in physiology and disease. , 2008, Hypertension.

[15]  F. Autschbach,et al.  Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin‐associated protein β1 gene CTNNB1 for patients with Wilms tumors , 2008 .

[16]  C. Choong,et al.  PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. , 2008, Blood.

[17]  P. Mattila,et al.  Filopodia: molecular architecture and cellular functions , 2008, Nature Reviews Molecular Cell Biology.

[18]  Johanna Andrae,et al.  Role of platelet-derived growth factors in physiology and medicine. , 2008, Genes & development.

[19]  Laura A. Sullivan,et al.  Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.

[20]  J. Mora,et al.  Different CTNNB1 mutations as molecular genetic proof for the independent origin of four Wilms tumours in a patient with a novel germ line WT1 mutation , 2007, Journal of Medical Genetics.

[21]  A. Reeve,et al.  Sequential WT1 and CTNNB1 mutations and alterations of β-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies , 2006, Journal of Clinical Pathology.

[22]  Gerald C. Chu,et al.  TGFβ superfamily signals are required for morphogenesis of the kidney mesenchyme progenitor population , 2004, Development.

[23]  J. Massagué,et al.  Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus , 2003, Cell.

[24]  Yuji Saito,et al.  Receptor Heterodimerization: Essential Mechanism for Platelet-Derived Growth Factor-Induced Epidermal Growth Factor Receptor Transactivation , 2001, Molecular and Cellular Biology.

[25]  C. Harris,et al.  Distinct pattern of p53 phosphorylation in human tumors , 2001, Oncogene.

[26]  C. Amos,et al.  Frequent Association of β-Catenin and WT1 Mutations in Wilms Tumors , 2000 .

[27]  K. Kinzler,et al.  Human Smad3 and Smad4 are sequence-specific transcription activators. , 1998, Molecular cell.

[28]  S. Schneider,et al.  Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[29]  D. Sens,et al.  Distinctive properties of an anaplastic Wilms' tumor and its associated epithelial cell line. , 1994, The American journal of pathology.

[30]  T. Gansler,et al.  Morphology and growth characteristics of epithelial cells from classic Wilms' tumors. , 1993, The American journal of pathology.

[31]  D. Sens,et al.  The in vitro growth, heterotransplantation, and immunohistochemical characterization of the blastemal component of Wilms' tumor. , 1987, The American journal of pathology.

[32]  H. B. Marsden,et al.  A cell line from Wilms' tumour with deletion in short arm of chromosome 11 , 1987, International journal of cancer.

[33]  D. Sens,et al.  The in vitro growth and characterization of the skeletal muscle component of Wilms' tumor. , 1985, The American journal of pathology.

[34]  C. S. Raymond,et al.  PDGF signaling specificity is mediated through multiple immediate early genes , 2007, Nature Genetics.